Molecular targeted therapies for cancer: Sorafenib monotherapy and its combination with other therapies (Review)

Oncology Reports

Volumn 27, Issue 5, 2012, Pages 1303-1311

  Ibrahim, Nuha ^a   Yu, Yan ^a   Walsh, William R ^a   Yang, Jia Lin ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Cancer; Combination therapy; Review; Sorafenib; Targeted therapy

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; DACARBAZINE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; GEFITINIB; GEMCITABINE; INTERLEUKIN 2; IRINOTECAN; LETROZOLE; PACLITAXEL; PEGINTERFERON ALPHA2B; PLACEBO; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN MCL 1; RAF PROTEIN; SORAFENIB; TEMOZOLOMIDE; TIPIFARNIB; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADVANCED CANCER; ALOPECIA; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BILE DUCT CARCINOMA; BLEEDING; CANCER INHIBITION; CANCER RADIOTHERAPY; CARCINOSARCOMA; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DESQUAMATION; DIARRHEA; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG POTENCY; DRUG POTENTIATION; DRUG RESISTANCE; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HAND FOOT SYNDROME; HEAD AND NECK CARCINOMA; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NASOPHARYNX CARCINOMA; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SARCOMA; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN DISEASE; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STOMACH ADENOCARCINOMA; THYROID CANCER; UNSPECIFIED SIDE EFFECT; UTERUS CARCINOMA; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; COMBINED MODALITY THERAPY; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIDINES;

EID: 84863283404     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1675     Document Type: Review

References (60)

1. Wilhelm S, Carter C, Lynch M, et al: Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5: 835-844, 2006. (Pubitemid 44480537)
2. Dal Lago L, D'Hondt V and Awada A: Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. Oncologist 13: 845-858, 2008.
3. Liu L, Cao Y, Chen C, et al: Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tum or angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66: 11851-11858, 2006. (Pubitemid 46094197)
4. Murdoch D and Sager J: Will targeted therapy hold its promise? An evidence-based review. Curr Opin Oncol 20: 104-111, 2008. (Pubitemid 350190989)
5. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM and Lynch M: Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7: 3129-3140, 2008.
6. McDermott DF, Sosman JA, Gonzalez R, et al: Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol 26: 2178-2185, 2008.
7. Wilhelm SM, Carter C, Tang L, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099-7109, 2004. (Pubitemid 39331023)
8. Longo R and Gasparini G: Challenges for patient selection with VEGF inhibitors. Cancer Chemother Pharmacol 60: 151-170, 2007. (Pubitemid 46742547)
9. Iyer R, Fetterly G, Lugade A and Thanavala Y: Sorafenib: a clinical and pharmacologic review. Exp Opin Pharmacother 11: 1943-1955, 2010.
10. Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134, 2007. (Pubitemid 46089673)
11. Ratain MJ, Eisen T, Stadler WM, et al: Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 2505-2512, 2006. (Pubitemid 46630627)
12. Miyake H, Kurahashi T, Yamanaka K, et al: Impact of sorafenib on health-related quality of life in Japanese patients with metastatic renal cell carcinoma: a prospective evaluation. BJU Int 106: 1643-1647, 2010.
13. Bukowski R, Cella D, Gondek K and Escudier B; Sorafenib TARGETs Clinical Trial Group: Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol 30: 220-227, 2007. (Pubitemid 46884139)
14. Rimassa L and Santoro A: The present and the future landscape of treatment of advanced hepatocellular carcinoma. Dig Liver Dis 42: S273-S280, 2010.
15. Cheng AL, Kang YK, Chen Z, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34, 2009.
16. Guan YS and He Q: Sorafenib: activity and clinical application in patients with hepatocellular carcinoma. Exp Opin Pharmacother 12: 303-313, 2011.
17. Wang Z, Hu J, Qiu SJ, et al: An investigation of the effect of sorafenib on tumour growth and recurrence after liver cancer resection in nude mice independent of phosphorylated extracellular signal-regulated kinase levels. Exp Opin Invest Drugs 20: 1039-1045, 2011.
18. Puxeddu E, Romagnoli S and Dottorini ME: Targeted therapies for advanced thyroid cancer. Curr Opin Oncol 23: 13-21, 2011.
19. Gupta-Abramson V, Troxel AB, Nellore A, et al: Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26: 4714-4719, 2008.
20. Eisen T, Ahmad T, Flaherty KT, et al: Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer 95: 581-586, 2006. (Pubitemid 44325897)
21. Fedorenko IV, Paraiso KH and Smalley KS: Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. Biochem Pharmacol 82: 201-209, 2011.
22. Azad NS, Posadas EM, Kwitkowski VE, et al: Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 26: 3709-3714, 2008.
23. Lee JM, Sarosy GA, Annunziata CM, et al: Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity. Br J Cancer 102: 495-499, 2010.
24. Duran I, Hotté SJ, Hirte H, et al: Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors. Clin Cancer Res 13: 4849-4857, 2007. (Pubitemid 47294792)
25. Spigel DR, Burris HA III, Greco FA, et al: Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small cell lung cancer. J Clin Oncol 29: 2582-2589, 2011.
26. Martinelli E, Troiani T, Morgillo F, et al: Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells. Clin Cancer Res 16: 4990-5001, 2010.
27. Escudier B, Lassau N, Angevin E, et al: Phase I trial of sorafenib in combination with IFN α-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res 13: 1801-1809, 2007. (Pubitemid 46952949)
28. Gollob JA, Rathmell WK, Richmond TM, et al: Phase II trial of sorafenib plus interferon α2b as first-or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol 25: 3288-3295, 2007. (Pubitemid 47325614)
29. Egberts F, Gutzmer R, Ugurel S, et al: Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial. Ann Oncol 22: 1667-1674, 2011.
30. Richly H, Henning BF, Kupsch P, et al: Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann Oncol 17: 866-873, 2006.
31. Abou-Alfa GK, Johnson P, Knox JJ, et al: Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 304: 2154-2160, 2010.
32. Sun W, Powell M, O'Dwyer PJ, Catalano P, Ansari RH and Benson AB III: Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol 28: 2947-2951, 2010.
33. Okamoto I, Miyazaki M, Morinaga R, et al: Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Invest New Drugs 28: 844-853, 2010.
34. Schiller JH, Flaherty KT, Redlinger M, et al: Sorafenib combined with carboplatin/paclitaxel for advanced non-small cell lung cancer: a phase I subset analysis. J Clin Oncol 24: 7194, 2006.
35. Hauschild A, Agarwala SS, Trefzer U, et al: Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 27: 2823-2830, 2009.
36. Bellmunt J, Trigo JM, Calvo E, et al: Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06). Lancet Oncol 11: 350-357, 2010.
37. Suen AW, Galoforo S, Marples B, et al: Sorafenib and radiation: a promising combination in colorectal cancer. Int J Radiat Oncol Biol Phys 78: 213-220, 2010.
38. Tang WY, Chau SP, Tsang WP, Kong SK and Kwok TT: The role of Raf-1 in radiation resistance of human hepatocellular carcinoma Hep G2 cells. Oncol Rep 12: 1349-1354, 2004.
39. Plastaras JP, Kim SH, Liu YY, et al: Cell cycle-dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res 67: 9443-9454, 2007. (Pubitemid 47535934)
40. Chang YS, Adnane J, Trail PA, et al: Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 59: 561-574, 2007. (Pubitemid 46295136)
41. Wilhelm S and Chien DS: BAY 43-9006: preclinical data. Curr Pharm Des 8: 2255-2257, 2002. (Pubitemid 35189898)
42. Sharma A, Trivedi NR, Zimmerman MA, Tuveson DA, Smith CD and Robertson GP: Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res 65: 2412-2421, 2005. (Pubitemid 40490153)
43. Ulivi P, Arienti C, Amadori D, et al: Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines. J Cell Physiol 220: 214-221, 2009.
44. Chapuy B, Schuelper N, Panse M, et al: Multikinase inhibitor sorafenib exerts cytocidal efficacy against Non-Hodgkin lymphomas associated with inhibition of MAPK14 and AKT phosphorylation. Br J Haematol 152: 401-412, 2011.
45. Huber S, Oelsner M, Decker T, et al: Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1. Leukemia 25: 838-847, 2011.
46. Blumenschein GR Jr, Gatzemeier U, Fossella F, et al: Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol 27: 4274-4280, 2009.
47. Adjei AA, Blumenschein GR Jr, Mandrekar S, Hillman S, Gatzemeier U and Heigener D: Long-term safety and tolerability of sorafenib in patients with advanced non-small cell lung cancer: a case-based review. Clin Lung Cancer 12: 212-217, 2011.
48. Steinbild S, Mross K, Frost A, et al: A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Br J Cancer 97: 1480-1485, 2007. (Pubitemid 350175850)
49. Maki RG, D'Adamo DR, Keohan ML, et al: Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 27: 3133-3140, 2009.
50. Elser C, Siu LL, Winquist E, et al: Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 25: 3766-3773, 2007. (Pubitemid 47372619)
51. Bengala C, Bertolini F, Malavasi N, et al: Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. Br J Cancer 102: 68-72, 2009.
52. Nimeiri HS, Oza AM, Morgan RJ, et al: A Phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol 117: 37-40, 2010.
53. Hong DS, Sebti SM, Newman RA, et al: Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin Cancer Res 15: 7061-7068, 2009.
54. Adjei AA, Molina JR, Mandrekar SJ, et al: Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer. Clin Cancer Res 13: 2684-2691, 2007. (Pubitemid 46788036)
55. Procopio G, Verzoni E, Bracarda S, et al: Sorafenib with interleukin- 2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial. Br J Cancer 104: 1256-1261, 2011.
56. Bonelli MA, Fumarola C, Alfieri RR, et al: Synergistic activity of letrozole and sorafenib on breast cancer cells. Breast Cancer Res Treat 124: 79-88, 2010.
57. Piguet AC, Saar B, Hlushchuk R, et al: Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma. Mol Cancer Ther 10: 1007-1017, 2011.
58. Eisen T, Marais R, Affolter A, et al: Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. Br J Cancer 105: 353-359, 2011.
59. Amaravadi RK, Schuchter LM, McDermott DF, et al: Phase II trial of temozolomide and sorafenib in advanced melanoma patients with or without brain metastases. Clin Cancer Res 15: 7711-7718, 2009.
60. Mross K, Steinbild S, Baas F, et al: Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib. Eur J Cancer 43: 55-63, 2007. (Pubitemid 46054474)